News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Pharmalucence, Inc. Announces FDA Approval for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Breast Cancer Patients
July 25, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BEDFORD, Mass.--(BUSINESS WIRE)--Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
COVID-19
FDA assembles vaccine experts to update COVID-19 formulation
May 27, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote
May 27, 2026
·
4 min read
·
Tristan Manalac
Regulatory
Makary’s reforms will live on at FDA even as leadership turns over
May 27, 2026
·
2 min read
·
Tristan Manalac
Adcomms
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm
May 22, 2026
·
2 min read
·
Tristan Manalac